CD19 and cancer: The link between gut dysbiosis and both immune-related adverse events and nonresponse to cancer immunotherapy across multiple settings including anti-PD-1 ICI and anti-CD19 chimeric antigen receptor T-cell therapy is increasingly appreciated [10,54,55].